| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 12/08/2022 | 352.08% | Maxim Group | → $4 | Upgrades | Hold → Buy |
| 11/08/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 09/06/2022 | 578.12% | Laidlaw & Co. | → $6 | Initiates Coverage On | → Buy |
| 03/12/2021 | 1256.24% | Brookline Capital | → $12 | Initiates Coverage On | → Buy |
| 03/03/2021 | 804.16% | Maxim Group | → $8 | Initiates Coverage On | → Buy |
What is the target price for NLS Pharmaceutics (NLSP)?
The latest price target for NLS Pharmaceutics (NASDAQ: NLSP) was reported by Maxim Group on December 8, 2022. The analyst firm set a price target for $4.00 expecting NLSP to rise to within 12 months (a possible 352.08% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for NLS Pharmaceutics (NLSP)?
The latest analyst rating for NLS Pharmaceutics (NASDAQ: NLSP) was provided by Maxim Group, and NLS Pharmaceutics upgraded their buy rating.
When is the next analyst rating going to be posted or updated for NLS Pharmaceutics (NLSP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NLS Pharmaceutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NLS Pharmaceutics was filed on December 8, 2022 so you should expect the next rating to be made available sometime around December 8, 2023.
Is the Analyst Rating NLS Pharmaceutics (NLSP) correct?
While ratings are subjective and will change, the latest NLS Pharmaceutics (NLSP) rating was a upgraded with a price target of $0.00 to $4.00. The current price NLS Pharmaceutics (NLSP) is trading at is $0.88, which is within the analyst's predicted range.